In the multi-trillion dollar pharmaceutical industry, CEOs and senior executives at large drugmakers frequently receive multi-million dollar compensation packages. In 2025, the industry publication MM+M tracked the remuneration of CEOs and top management teams at leading global pharmaceutical firms, along with other prominent biotech, life sciences, medical technology, and diagnostics companies. The analysis also compared whether 2025 executive pay increased, decreased, or remained static relative to 2024.

Eli Lilly, bolstered by the strong performance of its GLP-1 drugs Zepbound and Mounjaro, experienced another year of explosive growth, solidifying its position as a top global pharmaceutical company. Additionally, Lilly completed two multi-billion dollar acquisitions and became the first healthcare company to achieve a market capitalization exceeding $1 trillion. Correspondingly, the total compensation for Lilly CEO David Ricks reached $36.6 million in 2025, a 25% increase from the previous year. In his ninth year leading the company, Ricks's compensation package consisted of: base salary: $1.7 million; stock awards: $23.3 million; non-equity incentive plan compensation: nearly $6.5 million; change in pension value: $4.4 million; and other benefits: $736,201. Furthermore, the median employee pay at Lilly in 2025 was $125,100, resulting in a CEO-to-median-employee pay ratio of 293:1, one of the highest levels recorded last year and significantly exceeding peers: AstraZeneca (176:1), Sanofi (167.2:1), and GSK (167:1). The second-highest-paid executive at Lilly was Chief Scientific Officer and President of Lilly Research Laboratories and Lilly Immunology, Daniel Skovronsky, with compensation of $17.7 million. In 2025, Lilly's diabetes and weight-loss drugs continued to sell strongly, driving revenue up 45% to $65.2 billion. The products Mounjaro and Zepbound alone contributed $36.5 billion in revenue, accounting for 56% of the company's annual sales. Recently, Lilly introduced a new program allowing employers to subsidize GLP-1 drugs for employees directly at a cash price of $449 for Zepbound, bypassing insurance companies. The company stated this initiative aims to reduce barriers to access for weight-loss medications.

In her final year as CEO of GSK, Emma Walmsley's total compensation reached £15.68 million (approximately $20.94 million) in 2025, a nearly 50% increase from the $13.3 million received in 2024. Walmsley's pay package comprised: fixed pay: £2.1 million ($2.82 million); annual bonus: £3.52 million ($4.68 million); and vested long-term incentive awards: £10.05 million ($13.36 million). Under the terms for her final year, had GSK's share price increased by 50%, Walmsley could have earned a maximum annual package of $27.1 million. The CEO-to-median-employee pay ratio at GSK for 2025 was 167:1, higher than the 123:1 ratio in 2024. Luke Miels, the former Chief Commercial Officer who became CEO on January 1, received a starting salary of £1.375 million ($1.83 million). GSK Board Chairman Sir Jonathan Symonds commented, "The new policy is designed to incentivize management to deliver superior performance and more closely align pay with shareholder returns." A new compensation structure implemented in 2025 allocates 20% weighting to R&D pipeline performance, ensuring executive pay is directly linked to key research milestones. GSK's revenue grew 7% in 2025 to £32.7 billion, driven primarily by Specialty Medicines and Vaccines, which grew 17% and 2%, respectively. Like other major pharmaceutical companies facing potential drug tariffs from the Trump administration, GSK committed to investing $30 billion in the US over five years for R&D infrastructure.

Bayer CEO Bill Anderson's total compensation for 2025 was $7 million, marking the second consecutive year of a pay cut. His 2024 compensation was $9.6 million, which itself represented a 21% decrease from 2023. Anderson's 2025 pay consisted of: base salary: $2.6 million; short-term incentives: over $2.8 million; pension installments: over $1 million; and other benefits: $534,898. Bayer also disclosed that Anderson did not receive an allocation from the 2022 Long-Term Incentive Plan (allocated prior to his appointment) and that neither his target nor maximum compensation was increased for 2025. Bayer's CEO-to-median-employee pay ratio for 2025 was 53.3:1, slightly higher than the 52.8:1 ratio in 2024. The total compensation for Bayer's Supervisory Board was just over $6 million. The company stated, "The target total compensation for ordinary members of the Bayer Management Board (excluding the CEO), approximately $4.53 million, is significantly below the international peer group median (approximately $5.69 million) and is aligned with peer target pay increases." Bayer continues to navigate a challenging strategic turnaround: its full-year financial results met analyst expectations, but its profit guidance for 2026 fell short of market forecasts. Additionally, in late February, Bayer reached a settlement regarding lawsuits alleging its Roundup herbicide causes non-Hodgkin's lymphoma, agreeing to pay $7.25 billion.

AstraZeneca CEO Pascal Soriot's total remuneration for the 2025 fiscal year was £17.7 million (approximately $23.9 million), a significant increase from the £14.7 million ($1.99 billion as stated, but likely a typo; context suggests ~$19.9 million) in 2024. The CEO-to-median-employee pay ratio for AstraZeneca's UK staff was 176:1. Soriot's compensation breakdown was: base salary: £1.5 million; taxable benefits: £143,000; pension: £170,000; annual bonus: £4.3 million; and long-term incentives: £11.6 million. Sheri McCoy, Chair of AstraZeneca's Remuneration Committee, stated in the annual report, "We remain committed to performance-related pay, setting challenging targets that link rewards to long-term shareholder value and the 'Ambition 2030' strategy." AstraZeneca delivered a strong performance in 2025, with revenue growing 9% to $58.7 billion. Recently, the company listed on the New York Stock Exchange and announced plans to invest over RMB 100 billion additionally in China by 2030. Like many large pharma firms last year, amid threats of high tariffs on drugs from the Trump administration, AstraZeneca pledged $50 billion to support local sourcing of its products.

Sanofi CEO Paul Hudson's total compensation for the 2025 fiscal year was approximately $13.02 million. The CEO-to-employee pay ratio was 167.2:1, up from 166.3:1 in 2024. Hudson's compensation in recent years was: 2023: $11.7 million; 2024: $10.7 million; 2025: $13.02 million. His 2025 pay package consisted of: fixed compensation: $1.9 million; annual variable compensation: over $3.1 million; equity compensation: over $8 million; and benefits-in-kind: nearly $16,000. In February, Sanofi announced that Paul Hudson would step down as CEO on February 17 (having led since 2019) and would not receive performance shares for the 2026 fiscal year. Subsequently, Sanofi appointed former Merck KGaA CEO Belén Garijo to the role. Garijo's total compensation in 2024 was €6.7 million (approximately $7.2 million), down from €10.5 million in 2023. Belén Garijo is scheduled to officially assume her position following the company's Annual General Meeting on April 29. During the transition period, Olivier Charmeil, Executive Vice President and Head of General Medicines globally, who has been a member of the Executive Committee since 2011, will serve as interim CEO. Paul Hudson's departure after seven years at the helm comes as Sanofi faced pricing pressures and challenges in its US vaccines business in 2025. While full-year results met expectations, they did not deliver significant positive surprises. Sanofi anticipates high single-digit sales growth in 2026, with continued profit expansion.

Novo Nordisk's new CEO, Maziar Mike Doustdar, received compensation of 20.7 million Danish kroner (approximately $3.29 million) during his first few months in the role. The company's annual remuneration report stated that its pay benchmarks consider "external referencing and individual factors." Doustdar took over in early August 2025, following the departure of former CEO Lars Fruergaard Jørgensen after a challenging period. Jørgensen's total compensation for 2025 was $19.65 million, comprising: compensation during notice period: $3.53 million; payment in lieu of notice: $5.8 million; non-compete compensation: $3.5 million; and severance payment for 34 years of service: $6.82 million. Jørgensen's recent compensation was: 2023: $9.9 million; 2024: $8 million. Novo Nordisk's CEO-to-median-employee pay ratio for 2025 was 37:1, a substantial decrease from 63:1 in 2024 and 76:1 in 2023, which the company attributed to the management transition and a reduction in variable executive pay. Despite the continued high popularity of its blockbuster drugs Wegovy and Ozempic, Novo Nordisk faced intense competition throughout much of 2025 in the GLP-1 arena from rivals including Eli Lilly and online weight-loss providers. According to the annual results released in February 2025, full-year sales increased by 6%, but operating profit declined slightly by 1%. Novo Nordisk's negative sales guidance for 2026 disappointed investors, leading to a significant drop in its share price.

Roche CEO Thomas Schinecker's total compensation for 2025 was approximately $13.3 million. Schinecker's pay structure included: base salary: $4.6 million; annual bonus: $3.9 million (paid in a mix of unrestricted and restricted shares); long-term incentives: $4.3 million; and pension: nearly $500,000. Schinecker's 2025 compensation represented a slight increase from the 10 million Swiss francs (approximately $11.1 million) he received in 2024. This pay rise was a reward for Roche's performance last year, during which the company's sales surpassed $80 billion and profit grew 13% to $28.3 billion. In late January, Roche signaled positive future prospects. The Swiss pharma giant announced that its core weight-loss candidate demonstrated significant weight reduction in mid-stage trials and plans to initiate Phase III studies this quarter. Roche also projected that profit growth would outpace sales growth in 2026, with adjusted earnings per share expected to achieve high single-digit growth at constant exchange rates. Additionally, the total compensation for all members of Roche's Group Executive Committee in 2025 was approximately $42.8 million: Pharmaceuticals CEO Teresa Graham: $2.3 million; CFO Dr. Alan Hippe: over $2 million; Diagnostics CEO Matt Sause: $1.6 million; and Chief Human Resources Officer Cristina A. Wilbur: $1.4 million.

Novartis CEO Vas Narasimhan's total compensation reached $32.4 million in 2025, a significant increase that far exceeded his 2024 pay of $21.4 million and was more than double his 2023 compensation of $15.3 million. A primary reason for the increase was the vesting of his 2023-2025 Long-Term Performance Plan (LTPP) at 188% of target. The Swiss pharmaceutical giant disclosed this compensation information alongside its annual report. Notably, former Bristol Myers Squibb CEO Giovanni Caforio, in his first year as Chairman of the Novartis Board, received compensation of 2.9 million Swiss francs (approximately $3.8 million). According to Novartis's latest financial report, full-year net sales grew 8% to $54.5 billion. However, fourth-quarter 2025 net sales increased by only 1%, impacted by intense generic competition in the US market. Sales of its core product Entresto declined sharply by 43% due to patent expiry, a drop partially offset by strong sales of Kisqali, Kesimpta, and Pluvicto. To advance its growth strategy, Novartis announced two collaboration deals in mid-January: acquiring rights to a pre-clinical Alzheimer's amyloid-targeting project from Saise Therapeutics for a $165 million upfront payment, and entering a global licensing and collaboration agreement with China-based company regarding an undisclosed peptide asset in the radio-ligand therapy area for a $50 million upfront payment.